消化道无创诊疗微系统的无线供能技术的研究

报道了一种消化道微创诊疗微系统的无线体外供能装置,它主要由利用锁相环的自动频率跟踪电路和采用移相的调功电路构成。实验表明,该供能装置能自动频率跟踪和调节输出功率,使接收能量稳定。     

旋转式组织工程生物反应器检测控制及驱动系统

目的 生物反应器是组织工程的重要载体,旋转式生物反应器是目前研究的热点.本文探讨了可提供优良环境条件的可控生物反应器系统的设计与实践.方法 系统采用PWM可调驱动直流电机等;同时可对温度等物理量进行检测,并反馈控制调节反应器;测控系统与PC连接,可实现远程视频监测控等,使整个组织生物反应器系统初步实现了分步式、自动化.结果 经实验系统培养所得到的细胞相对于一般培养细胞其生物学特性有相当的改善.结论自动化旋转式生物反应器驱动控制的实践具有较大的应用推广价值.     

PWM激活的淋巴细胞亚群的功能研究

用放射性标记化合物掺入法研讨ＰＷＭ诱导人血淋巴细胞亚群的功能及其调节。实验表明，ＰＷＭ细胞对ＬＰＳ活的Ｂ细胞转化有促进作用，受４０Ｇｙ辐照后，它的作用显著下降，但仍有一定加强效应。ＰＷＭ细胞对ＰＷＭ激活的淋巴细胞转化的促进作用不明显，对ＣｏｎＡ和ＰＨＡ激活的细胞无效。用玫瑰花环法分离Ｔ、Ｂ细胞，用ＣＤ４、ＣＤ３和Ｂ３株单克降抗体（ＭｃＡｂ），以亲和层析和Ｐａｎｎｉｎｇ法分离各淋巴细胞亚群，分别研究ＰＷＭ对各亚群的激活及相互调节作用．结果表明：Ｂ细胞被ＰＷＭ激活强于Ｔ细胞，ＰＷＭ对Ｂ和非ＣＤ４细胞激活作用相当，ＣＤ２细胞次之，ＣＤ４细胞最弱．Ｔ细胞或ＣＤ４细胞与Ｂ细胞均有协同作用，前者作用更大．ＰＷＭ－非ＣＤ４和ＰＷＭ—Ｂ细胞无协同作用，ＣＤ６细胞与Ｂ细胞有抑制作用。     

商陆体外诱导抗体产生方法的改进及其应用

本文介绍一种商陆体外诱导抗体产生及其测定方法。该法在低浓度FCS的培养液中,将淋巴细胞用商陆连续诱导6d,然后用ELISA法测定淋巴细胞分泌到上清液中的Ig。因改二次培养为一次,不仅操作简化,而且节省淋巴细胞,易于在临床检测中应用。此法在中药研究中得到满意结果。     

凝集素美洲商陆和IL-2共同激活的单核细胞抗白血病作用的研究

采用MTT法研究了美洲商陆(PWM)和IL-2共同激活的单核细胞对人类白血病原代培养细胞的体外杀伤作用。结果表明,激活的单核细胞对白血病细胞具有明显的杀伤作用,其杀伤活性可达73.39％-83.73％。杀伤活性的强弱与白血病的细胞类型没有必然的联系;此外,来源于不同个体的白血病细胞对单核细胞杀伤作用的敏感性不同。采用激活的单核细胞对自体骨髓进行净化,用于造血干细胞移植,具有干细胞损失少,净化效果好,毒副作用小等特点,其应用前景良好。     

模糊-PI控制在血液透析机温度控制中的应用

目的:设计一种应用于血液透析机的温度控制系统。方法:提出了一种基于模糊控制和PI控制相结合的方法,在偏差较大时采用模糊控制算法,偏差较小时采用PI控制算法来调节PWM的占空比,从而调节加热棒的功率,实现对血液透析机的温度控制。结果:模糊-PI控制下系统温度超调为0.5%,稳态误差为±0.2℃,控制调整时间约为2 min。结论:该控制方法响应速度快、超调量小、稳态精度高,具有良好的动态性能和稳定度,实现对透析液温度的精确控制。     

Lymphocyte responsiveness to phytohemagglutinin (PHA) and serum inhibitory effect in patients with gastric cancer

The in vitro lymphocyte response to PHA was determined in patients with gastric cancer in various stages prior to the sugical treatment. The lymphocyte responsiveness in the presence of homologous pooled AB serum in patients of stages II, III and IV were markedly reduced as compared with that in healthy controls (stages II, III; p<0.05, stage IV; p<0.01). Inhibition of normal lymphocyte responsiveness to PHA by serum from patients in stages III and IV were statistically significant as compared with that in stage I (stage III; p<0.05, stage IV; p<0.01). Serum inhibitory effect on the normal lymphocyte responsiveness was significant only in the advanced stage. It was concluded that the suppression of the immune response in the early stage of gastric cancer was mainly due to the impairment of lymphocyte itself, which advanced with the progress of the stage and was modified by the serum inhibitory effect in advanced stages. In patients with advanced cancer, the higher was the lymphocyte responsiveness to PHA and PWM prior to the initial treatment, the more effective was the immunotherapy. This shows that the indication of the immunotherapy in patients with advanced cancer could be initiated. Furthermore, the correlation between the lymphocyte responsiveness to PHA and the clinical results of immunotherapy was discussed. Supported in part by a Grant-in-Aid for Cancer Research from the Ministry of Education, Science and Culture.     

Influence of in vivo interferon treatment on mitogen responsiveness of T-and B-cells is dependent on the mouse genotype

Intravenous inoculation of moderate doses of viral interferon (up to 10(4) I.U./mouse) induced subsequent modification of the mitogen responsiveness of T-and B-lymphocytes from the spleen. The modulation, however, was dependent on the mouse genotype. Whereas BALB/c mice demonstrated enhanced T-cell responses (especially to PHA), C57B1/6 mice were generally suppressed in their T-cell response by the same treatment. B-cell proliferation to LPS showed a moderate enhancement in both strains, probably due to activation of accessory cells.     

Antibody producing human-human hybridomas. I. Technical aspects

Technical aspects of generation of antibody-secreting human-human hybridomas are evaluated as based on 100 human-human fusions with a human B-lymphoma cell line (RH-L4) or the SKO-007 myeloma cell line as malignant fusion partners, and compared with similar fusion conditions in the mouse hybridoma system. The yield of hybrids was significantly lower when normal peripheral blood lymphocytes were used as fusion partners as compared with spleen lymphocytes, but could be substantially improved by increasing the amount of mitotic active B-lymphocytes by mitogen stimulation of the lymphocytes, preferably in HAT medium, prior to fusion. Furthermore, human hybrids grew slower and had a higher degree of chromosomal instability than usually observed in the mouse hybridoma system. Thus, out of 72 fusions, only 3 stable hybrids with antibody production against a predefined antigen were established. The importance of improved sources of human B-lymphocytes for human-human hybridoma production is discussed and methods of obtaining such improvement suggested.